SIAL Shenzhen 2025: South China's Premier Food & Beverage Sourcing Event Will Return This September
Global Innovation Meets Regional Excellence
The show will feature 14 product zones across the entire F&B value chain, including:
Ingredients & Spices: Nutritional extracts, fermented sauces, rare spices.
Frozen & Ready Meals: Self-heating hotpots, rice bowls, frozen veggies.
Snacks & Bakery: Premium chocolates, seaweed crisps, functional snacks, fusion pastries with goji berries and matcha.
Beverages & New Tea Drinks: Heritage teas, fruit infusions, trending milk teas.
Fresh Produce & Frozen Ingredients: Organic greens, IQF vegetables, traceable grains.
Prepared Foods & Convenience Meals: Instant noodles, frozen dumplings, banquet-ready meals.
Alcoholic Beverages: Georgian wine, Chinese Baijiu, rice wine, regional craft beer.
Other Key Sectors: Meat & seafood, oils, condiments, and more.
Tailored Trade Services for Global Buyers
SIAL Shenzhen delivers efficient sourcing through:
One-on-One Matchmaking and private negotiation rooms.
Fast-Track Access & VIP Lounges for qualified buyers.
72-Hour Advance Preview of products and exhibitors.
Multilingual Interpretation on-site.
New SIAL Society Top Buyer Programme – a premium networking club connecting importers, foodservice operators, and retailers.
Chinese Regional Pavilions with Signature Products
Green Yunnan Delights Pavilion: Highland Pu'er tea, wild mushrooms, black truffle crisps, and yak milk snacks from China's mountainous southwest.
Hubei Premium Pavilion: Lotus root chips, clean-label noodles, river fish delicacies, and preserved eggs from the Yangtze River region.
Authentic Shenyang Pavilion: Northeastern sausages, pickled cabbage, soybean paste, and traditional "Dongbei" frozen dumplings.
Heilongjiang Forest Gourmet Pavilion: Pine nuts, forest honey, wild blueberries, and grain-based health products from China's northern frontier.
Discover What's Next in Food Consuming Scenario?
SIAL Innovation – future-forward products in health, sustainability, and plant-based.
SIAL Snack Awards – global snack tasting and trend discovery.
SIAL Chic Tea Contest & SIAL CUP Barista – showcasing the evolution of tea and coffee in Asia.
SIAL Shenzhen 2025 is your gateway to food innovation in South China - connecting the world's top producers with Asia's most dynamic buyers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
34 minutes ago
- Korea Herald
S. Korea, China FMs agree to make upcoming APEC summit 'new turning point' in ties
The top diplomats of South Korea and China agreed Monday to work together to make the upcoming Asia-Pacific Economic Cooperation summit a "new turning point" in bilateral relations, as they held their first telephone call, the South Korean Foreign Ministry said. Foreign Minister Cho Hyun and Chinese Foreign Minister Wang Yi expressed this view during the 45-minute phone conversation, reaffirming their commitment to advance the bilateral strategic cooperative partnership in a "steady and mature" manner, the ministry said in a release. "They agreed to work together to ensure that the upcoming APEC summit in Gyeongju serves as a new turning point in bilateral ties and to deliver tangible outcomes in practical cooperation that can be felt by the peoples of both countries," it said. They also agreed to maintain the positive momentum in bilateral ties through high-level exchanges. The APEC summit is set to take place in the southeastern South Korean city from Oct. 31 to Nov. 1. Chinese President Xi Jinping is widely expected to attend the multilateral meeting. China is the host for next year's APEC summit. Congratulating Cho on his inauguration, Wang expressed a willingness to maintain a close working relationship with him, according to the ministry. Cho, in turn, said he hopes to closely work with Wang to further develop the Seoul-Beijing ties. Cho took office last Monday. He also extended an invitation for Wang to visit South Korea, and Wang responded that he would visit at a mutually convenient time, according to the ministry. (Yonhap)
Korea Herald
2 hours ago
- Korea Herald
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the China National Medical Products Administration (NMPA) has approved XPOVIO ® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy, a new indication of XPOVIO ®. This approval for XPOVIO ® is based on the data of the BENCH trial, a randomized, controlled, open-label, multicenter Phase III bridging study which compared the safety and efficacy of XVd and Vd regimens in 154 Chinese patients with R/R MM who have received one to three prior lines of therapy. The efficacy and safety data of the BENCH study are generally consistent with those from the global, multicenter, Phase III BOSTON study and met the objectives of the bridging study which showed: Clear superiority of the XVd regimen: compared to the Vd regimen, the XVd regimen demonstrated better clinical efficacy, longer PFS and DOR, a higher ORR, a higher rate of very good partial response (VGPR) or deeper responses and minimal residual disease (MRD) negativity, as well as a trend of prolonged OS. Notable clinical benefits for elderly patients: the study observed particularly notable efficacy in the cohort of elderly patients aged ≥65, validating XPOVIO ® as a better treatment option for this patient population. Prof. Jin Lu, principal investigator of the BENCH study from Peking University People ' s Hospital, said, "MM is the second most common hematologic malignancy. The clinical application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in the first-line setting have resulted in longer overall survival for patients. However, the condition remains incurable with most patients end up relapsing. As a novel inhibitor of the nuclear export protein that adopts a novel mechanism of action, selinexor was proven by the BENCH study to be significantly efficacious in Chinese patients with MM. This approval for XPOVIO ® is a great news for patients with R/R MM, especially those relapsing for the first time." Prof. Jian Hou, principal investigator of the BENCH study from Shanghai Jiaotong University School of Medicine Affiliated Renji Hospital, commented, "The incidence of MM has been steadily rising year after year. According to the Globocan statistics for 2022, there were 30,300 new cases of MM and 18,662 MM related deaths in China, a figure that highlights an urgent unmet clinical need. Selinexor in combination with bortezomib and dexamethasone incorporates a unique mechanism of action and demonstrated significant efficacy. Moreover, XPOVIO ® does not require intravenous administration, therefore provides clinicians a new treatment strategy that can effectively reduce burden on patients." With a novel mechanism of action, XPOVIO ® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). While bringing XPOVIO ® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO ®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO ® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO ® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact:
Korea Herald
2 hours ago
- Korea Herald
SMU issues its inaugural Sustainability Bond, raising S$150 million to advance environmental and social initiatives
SINGAPORE, July 28, 2025 /PRNewswire/ - - Singapore Management University (SMU) today announced that it has completed the issuance of a S$150 million Sustainability Bond. The proceeds of the Bond are earmarked for financing and refinancing green and social projects that deliver clear environmental and social benefits, as guided by SMU's newly established Sustainable Financing Framework. The Sustainability Bond, the first such bond by an Autonomous University (AU) in Singapore, was issued on 28 July 2025 at a coupon rate of 2.022% and will mature on 28 July 2032. The Sole Lead Manager and Bookrunner for the bond issuance was Oversea-Chinese Banking Corporation Limited (OCBC). SMU President, Professor Lily Kong, said, "This inaugural Sustainability Bond is more than just a financial instrument — it reflects our belief that universities must play a leading role in building a more sustainable and inclusive future. We've been guided by our Sustainability Blueprint since 2022 and are proud to contribute to the priorities set out in the Singapore Green Plan 2030. As a university, we take seriously our role in shaping future-ready graduates who are not only intellectually agile, but also attuned to the pressing challenges of our time. By embedding sustainability in our operations and investments, we hope to lead with purpose and conviction." "Launching this bond in our 25 th anniversary year feels especially meaningful — it signals our intent to grow with purpose, and to leave a positive, lasting impact on the communities we serve," she added. SMU Sustainable Finance Framework In June 2025, SMU established a holistic and comprehensive Sustainable Financing Framework which aligns SMU's financial practice with its sustainability goals (outlined in the SMU Sustainability Blueprint) and embodies SMU's deep commitment to sustainability and corporate social responsibility. The Framework outlines the criteria and guidelines for SMU to allocate and manage the proceeds raised from sustainable finance transactions. Developed in collaboration with its sole sustainability advisor, OCBC, the Framework provides the foundation for SMU to engage in sustainable finance transactions such as green, social and sustainability bonds and loans. It guides SMU's issuance of sustainable finance debt instruments to finance or refinance projects and assets that deliver measurable environmental and/ or social benefits. These include green buildings, energy efficiency upgrades, green infocommunications technology infrastructure, sustainable water and waste management, as well as programmes that promote inclusive education, knowledge sharing, and mental health and wellbeing. Mr Lim Boon Wee, SMU's Senior Vice President, Administration, said, "This bond issuance is a strategic milestone for SMU as we align our financial strategy with our sustainability goals, and channel capital to where it matters most. It enables us to finance infrastructure and initiatives that enhance environmental performance and social impact, while ensuring transparency and accountability to our stakeholders." The Framework received a Second Party Opinion from ratings agency, Moody's Investors Service (Moody's), affirming its alignment with internationally recognised standards and its significant contribution to sustainable outcomes. Moody's further assessed the Framework as having a significant contribution to sustainability, giving it an overall Sustainability Quality Score of SQS2 – Very Good. SMU also maintains a Aaa rating by Moody's, the highest possible rating in assessing creditworthiness, reflecting the University's robust institutional framework and healthy operating performance. First Sustainability Bond issuance by a Singapore university SMU's Sustainability Bond is the first such bond issued by an AU in Singapore, and is differentiated in the scope of impact. Apart from green initiatives with environmental benefits, SMU is committing a portion of the proceeds raised to fund social programmes that promote inclusive education benefitting its students from low-income families. This differs from Green Bonds (focusing solely on projects with environmental benefits) and Sustainability-Linked Bonds (which are tied to predefined sustainability performance targets only) previously issued by other universities in Singapore. Ms Elaine Lam, Head of Global Corporate Banking, OCBC, said, "With our strong track record in guiding clients through their green transition with strategic advisory and targeted financing solutions, we are excited to strengthen our long-standing partnership with SMU by supporting its first Sustainability Bond issuance covering both environmental projects as well as social programmes that promote inclusive education. A first by an autonomous university in Singapore, this bond issuance speaks to SMU's leadership in integrating sustainability into its core mission, potentially inspiring its students to become future leaders who advocate for both environmental stewardship and social equity." - End -
